Confidential Materials omitted and filed separately with theSecurities and Exchange Commission. Double asterisks denote omissions.Ophthotech Corp. • November 8th, 2017 • Pharmaceutical preparations
Reference is made to that certain Licensing and Commercialization Agreement dated as of May 19, 2014 (the “Agreement”), by and among Ophthotech Corporation, a Delaware corporation (“Ophthotech”), and Novartis Pharma AG, a Swiss company (“Novartis”). Ophthotech and Novartis are sometimes referred to individually as a “Party” and collectively as the “Parties.” Capitalized terms used but not defined herein shall have the meanings given to them in the Agreement.
